Skip to main content

Table 1 Baseline characteristics in the training set and validation set

From: Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation

Variable A-LMR ≥ 1 (N = 59) A-LMR < 1 (N = 50) p value
At diagnosis    
 Age, years, median (range) 53 (18–71) 56 (20–75) 0.2
 Gender    0.2
  Male 38 (64 %) 25 (50 %)  
  Female 21 (36 %) 25 (50 %)  
 LDH (U/L), median (range) 211 (116–928) 276.5 (137–1539) 0.04
 Extra-nodal site    0.05
  0 7 (12 %) 6 (12 %)  
  1 49 (83 %) 34 (68 %)  
  2 3 (5 %) 10 (20 %)  
 B symptoms    0.9
  Yes 17 (29 %) 15 (30 %)  
  No 42 (71 %) 35 (70 %)  
 Stage    <0.001
  I 2 (3 %) 1 (2 %)  
  II 26 (44 %) 5 (10 %)  
  III 9 (15 %) 12 (24 %)  
  IV 22 (38 %) 32 (64 %)  
 Bone marrow involvement    0.5
  Yes 15 (25 %) 16 (32 %)  
  No 44 (75 %) 34 (68 %)  
 Bulky disease    0.8
  Yes 3 (5 %) 6 (6 %)  
  No 56 (95 %) 47 (94 %)  
 Hemoglobin (g/dl), median (range) 12.5 (8.1–13.1) 12.5 (6.6–16.9) 0.6
 Platelets × 109/l, median (range) 231 (14–626) 214 (31–719) 0.06
 IPI score    0.01
  0 13 (22 %) 2 (4 %)  
  1 19 (32 %) 12 (24 %)  
  2 17 (29 %) 18 (36 %)  
  3 8 (13 %) 10 (20 %)  
  4 1 (2 %) 7 (14 %)  
  5 1 (2 %) 1 (2 %)  
 Performance status    0.3
  0 7 (12 %) 4 (8 %)  
  1 45 (76 %) 43 (86 %)  
  2 5 (8 %) 3 (6 %)  
  3 2 (45 %) 0 (0 %)  
 T-cell lymphoma histologies    0.9
  Anaplastic large cell 10 (17 %) 5 (13 %)  
 Angioimmunoblastic 15 (25 %) 15 (27 %)  
  Enteropathy-associated 6 (10 %) 3 (6 %)  
  Hepatosplenic 1 (2 %) 1 (2 %)  
  NK/T 7 (12 %) 6 (12 %)  
  Panniculitis 4 (7 %) 3 (6 %)  
  Peripheral 16 (27 %) 17 (34 %)  
IPI factors    
 Age, years    0.3
  60 18 (31 %) 20 (40 %)  
  ≤60 41 (69 %) 30 (60 %)  
 LDH (U/L)    0.03
  Normal 34 (58 %) 18 (36 %)  
  Abnormal 25 (42 %) 32 (64 %)  
 Performance status    0.3
  1 7 (12 %) 3 (6 %)  
  ≤1 52 (88 %) 47 (94 %)  
 Extra-nodal disease    0.02
  1 3 (5 %) 10 (20 %)  
  ≤1 56 (95 %) 40 (80 %)  
 Stage    <0.001
  I/II 28 (47 %) 6 (12 %)  
  III/IV 31 (53 %) 44 (88 %)  
IPI index    0.03
 2 10 (17 %) 18 (36 %)  
 ≤2 49 (83 %) 32 (64 %)  
Initial chemotherapy    0.9
 CHOP 58 (98 %) 49 (98 %)  
 SMILE 1 (2 %) 1 (2 %)  
Salvage chemotherapy (N = 51)    0.2
 CDE 2 (9 %) 0 (0 %)  
 DHAP 5 (21 %) 8 (29 %)  
 ICE 16 (70 %) 20 (71 %)  
Up-front transplant    0.09
 Yes 36 (61 %) 22 (44 %)  
 No 23 (39 %) 28 (56 %)  
At transplant    
 Pre-transplant clinical status    <0.001
  CR 51 (86 %) 25 (50 %)  
  PR 8 (15 %) 25 (50 %)  
 Plerixafor    0.8
  Yes 21 (36 %) 19 (38 %)  
  No 38 (64 %) 31 (62 %)  
 Infused CD34, median (range) 5.42 (2.25–13.44) 5.12 (2.04–15.65) 0.9
 Number of collections    0.08
  1 7 (12 %) 12 (24 %)  
  2 19 (32 %) 15 (30 %)  
  3 19 (32 %) 9 (18 %)  
  4 7 (12 %) 11 (22 %)  
  5 1 (2 %) 2 (4 %)  
  6 3 (5 %) 0 (0 %)  
  7 2 (3 %) 0 (0 %)  
  8 1 (2 %) 1 (2 %)  
 A-ALC, median (range) 0.68 (0.21–3.83) 0.44 (0.06–1.40) <0.001
 A-AMC, median (range) 0.45 (0.10–1.42) 0.78 (0.20–1.60) <0.001
 ALC-15, median (range) 0.71 (0.10–2.31) 0.41 (0.10–1.18) <0.001
 AMC-15, median (range) 0.43 (0.04–1.19) 0.90 (0.20–2.31) <0.001
 LMR-15 1.71 (0.24–15.5) 0.57 (0.08–3.18) <0.001
  1. Abbreviations: A-ALC autograft absolute lymphocyte count; ALC-15 day 15 absolute lymphocyte count post-autologous peripheral hematopoietic stem cell transplantation; A-AMC autograft absolute monocyte count; AMC-15 day 15 absolute monocyte count post-autologous peripheral hematopoietic stem cell transplantation; A-LMR autograft lymphocyte/monocyte ratio; CDE cyclophosphamide, doxorubicin, and etoposide; CR complete response; CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone; DHAP dexamethasone, cytarabine, and cisplatin; ICE ifosfamide, carboplatin, and etoposide; IPI International Prognostic Index; LDH lactate dehydrogenase; LMR- 15 day 15 lymphocyte/monocyte ratio post-autologous peripheral hematopoietic stem cell transplantation; PR partial response; SMILE methotrexate, leucovorin, ifosfamide, dexamethasone, etoposide, and pegaspargase